
ICON plc (NASDAQ:ICLR) (&#34;ICON&#34;), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the &#34;Issuer&#34;),

<p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=54582920&amp;newsitemid=20260804404882&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=f58958a31f469144565f39cea0587c28" shape="rect">ICON plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ICLR">ICLR</a>) ("ICON"), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the "Issuer"), intends to offer one or more series of senior notes (the "Notes"), in a private offering (the "Offering") with registration rights, subject to market and other conditions. The Notes will be guaranteed on a senior unsecured basis by ICON.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The net proceeds of the Offering are intended to be used to (i) repay all outstanding borrowings under ICON Global Treasury Unlimited Company’s bridge facility credit agreement (the "Bridge Secured Credit Facility"), (ii) repay all outstanding term loans under ICON’s senior secured term loan facility (the "Existing Term Loans") and (iii) redeem, in full, the Issuer’s outstanding 5.809% Senior Secured Notes due 2027 (the "2027 Notes").

</p><p xmlns="http://www.w3.org/1999/xhtml">
Upon repayment of the Bridge Secured Credit Facility and the Existing Term Loans, the collateral securing ICON’s revolving credit facility and ICON group’s existing notes will be automatically released, and the subsidiary guarantees under the existing notes will be automatically released. There can be no assurance that the proposed Offering will close and that the Bridge Secured Credit Facility and Existing Term Loans will be repaid, or that the collateral and guarantees will be released.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the Notes (and the guarantees) or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a notice of redemption under the indenture governing the 2027 Notes or an offer to purchase the 2027 Notes.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Notes (and the guarantees) are being offered (i) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and (ii) outside the United States pursuant to Regulation S under the Securities Act. None of the Notes or related guarantees have been registered under the Securities Act or the securities laws of any state or other jurisdiction, and the Notes (and such guarantees) may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and the securities laws of any applicable state or other jurisdiction. There can be no assurance that the proposed offering of Notes will be completed.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About ICON plc</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as at June 30, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Statements included herein which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue; the repayment of indebtedness (including, the completion of this offering, the repayment of the Bridge Secured Credit Facility or the Existing Terms Loans and the redemption of the 2027 Notes); the company&#39;s expectations regarding business momentum, market opportunity, demand trends, growth, and commercial performance; and the company&#39;s expectations with respect to its long-term value creation and competitive positioning. You can identify many forward-looking statements by words such as "aims," "anticipates," "believes," "continues," "could," "estimates," "expects," "focused," "guidance," "intends," "look," "may," "opportunities," "plans," "positions," "potential," "predicts," "projects," "seeks," "should," "will," "would" and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management’s current expectations and information currently available, including current economic and industry conditions. The forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially adversely affected. The risks and uncertainties include, but are not limited to, dependence on the pharmaceutical industry and certain clients, the need to regularly win projects and then to execute them efficiently and correctly, the challenges presented by rapid growth, competition and the continuing consolidation of the industry, the impact of market conditions on demand for the company&#39;s services, risks related to the company&#39;s ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers, and risks relating to the company&#39;s strategic partnerships, the dependence on certain key executives, changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs. Please also refer to the section entitled "Risk Factors" of our Annual Report on Form 20-F for the year ended December 31, 2025 for a discussion of some of the principal risks that could adversely affect our business, operations and financial results. The company’s forward-looking statements speak only as of the date of this document or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">ICON/ICLR-F</b>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260804404882r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260804404882/en/" rel="nofollow">https://www.businesswire.com/news/home/20260804404882/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Kate Haven Vice President Investor Relations +1888 381 7923
<br xmlns="http://www.w3.org/1999/xhtml"></br>Nigel Clerkin Chief Financial Officer +353 1 291 2000

</p>

ICLR

ICON Announces Private Offering of Notes

ICON plans private senior notes to refinance debt, boosting balance sheet

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>ICON plc (NASDAQ:ICLR) (&amp;#34;ICON&amp;#34;), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the &amp;#34;Issuer&amp;#34;),</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>ICON plc announced a private offering of senior notes by its issuer, ICON Investments Six DAC, to refinance debt and redeem the 2027 notes. If the offering closes, collateral on the revolver could be released and ICON&#039;s leverage could improve, enhancing financial flexibility.Completion remains uncertain; market conditions will largely drive timing and pricing, influencing ICLR sentiment.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ICON plans private senior notes offering to repay debt. Proceeds target bridge facility.</li><li>Notes to redeem 2027 notes; collateral release possible after repayment.</li><li>Repayment could release collateral on revolving facility; market impact uncertain.</li><li>Offering is for qualified institutional buyers; not registered in US.</li><li>ICON employs about 40,200 across 99 locations in 55 countries (6/30/2026).</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ICON plc (ICLR)</strong>: Publicly traded parent; debt refinancing could affect leverage, cash flow, and stock sentiment.</li><li><strong>ICON Investments Six DAC (N/A)</strong>: Issuing subsidiary; private offering facilitating debt refinancing; impact on ICON&#039;s balance sheet.</li><li><strong>5.809% Senior Secured Notes due 2027 (N/A)</strong>: Existing notes targeted for redemption; refinancing would shift debt stack.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category fits Corporate Developments as it describes a financing move impacting ICON&#039;s capital structure and leverage.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Potential collateral release could improve ICON&#039;s debt capacity and covenants.</li><li>Uncertainty on deal closure may cause near-term volatility in ICLR.</li><li>Successful refinancing could positively influence ICON&#039;s leverage metrics and investor sentiment for ICLR.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Issuer: ICON Investments Six DAC, a wholly-owned ICON plc subsidiary.</li><li>Notes: senior unsecured; guaranteed by ICON; private offering to QIBs under Rule 144A/Reg S.</li><li>Use of proceeds: repay Bridge Secured Credit Facility and Existing Term Loans; redeem 2027 notes.</li><li>Collateral release: secured collateral for revolver and notes to be released upon repayment.</li><li>Date: press release dated Aug 4, 2026; ICON employs ~40,200 across 99 locations in 55 countries.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term ICLR moves will hinge on progress of ICON&#039;s debt refinancing; positive if close, negative if delayed.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=54582920&amp;newsitemid=20260804404882&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=f58958a31f469144565f39cea0587c28" shape="rect">ICON plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ICLR">ICLR</a>) ("ICON"), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the "Issuer"), intends to offer one or more series of senior notes (the "Notes"), in a private offering (the "Offering") with registration rights, subject to market and other conditions. The Notes will be guaranteed on a senior unsecured basis by ICON.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The net proceeds of the Offering are intended to be used to (i) repay all outstanding borrowings under ICON Global Treasury Unlimited Company’s bridge facility credit agreement (the "Bridge Secured Credit Facility"), (ii) repay all outstanding term loans under ICON’s senior secured term loan facility (the "Existing Term Loans") and (iii) redeem, in full, the Issuer’s outstanding 5.809% Senior Secured Notes due 2027 (the "2027 Notes").

</p><p xmlns="http://www.w3.org/1999/xhtml">
Upon repayment of the Bridge Secured Credit Facility and the Existing Term Loans, the collateral securing ICON’s revolving credit facility and ICON group’s existing notes will be automatically released, and the subsidiary guarantees under the existing notes will be automatically released. There can be no assurance that the proposed Offering will close and that the Bridge Secured Credit Facility and Existing Term Loans will be repaid, or that the collateral and guarantees will be released.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the Notes (and the guarantees) or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a notice of redemption under the indenture governing the 2027 Notes or an offer to purchase the 2027 Notes.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Notes (and the guarantees) are being offered (i) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and (ii) outside the United States pursuant to Regulation S under the Securities Act. None of the Notes or related guarantees have been registered under the Securities Act or the securities laws of any state or other jurisdiction, and the Notes (and such guarantees) may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and the securities laws of any applicable state or other jurisdiction. There can be no assurance that the proposed offering of Notes will be completed.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About ICON plc</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as at June 30, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Statements included herein which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue; the repayment of indebtedness (including, the completion of this offering, the repayment of the Bridge Secured Credit Facility or the Existing Terms Loans and the redemption of the 2027 Notes); the company&#39;s expectations regarding business momentum, market opportunity, demand trends, growth, and commercial performance; and the company&#39;s expectations with respect to its long-term value creation and competitive positioning. You can identify many forward-looking statements by words such as "aims," "anticipates," "believes," "continues," "could," "estimates," "expects," "focused," "guidance," "intends," "look," "may," "opportunities," "plans," "positions," "potential," "predicts," "projects," "seeks," "should," "will," "would" and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management’s current expectations and information currently available, including current economic and industry conditions. The forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially adversely affected. The risks and uncertainties include, but are not limited to, dependence on the pharmaceutical industry and certain clients, the need to regularly win projects and then to execute them efficiently and correctly, the challenges presented by rapid growth, competition and the continuing consolidation of the industry, the impact of market conditions on demand for the company&#39;s services, risks related to the company&#39;s ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers, and risks relating to the company&#39;s strategic partnerships, the dependence on certain key executives, changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs. Please also refer to the section entitled "Risk Factors" of our Annual Report on Form 20-F for the year ended December 31, 2025 for a discussion of some of the principal risks that could adversely affect our business, operations and financial results. The company’s forward-looking statements speak only as of the date of this document or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">ICON/ICLR-F</b>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260804404882r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260804404882/en/" rel="nofollow">https://www.businesswire.com/news/home/20260804404882/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Kate Haven Vice President Investor Relations +1888 381 7923
<br xmlns="http://www.w3.org/1999/xhtml"></br>Nigel Clerkin Chief Financial Officer +353 1 291 2000

</p>

ICON plc announced a private offering of senior notes by its issuer, ICON Investments Six DAC, to refinance debt and redeem the 2027 notes. If the offering closes, collateral on the revolver could be released and ICON's leverage could improve, enhancing financial flexibility.Completion remains uncertain; market conditions will largely drive timing and pricing, influencing ICLR sentiment.

News insight

ICON Announces Private Offering of Notes

AI summary

Sentiment rationale

Key facts

Corporate Developments